Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289549 · ClinicalTrials.gov registry record · Phase 2
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00289549 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT00289549, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).
Interventions
- DRUG forodesine hydrochloride (BCX-1777)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00289549
The ClinicalTrials.gov registry entry for NCT00289549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which forodesine hydrochloride (BCX-1777) is the first listed.
NCT00289549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00289549 about?
NCT00289549 is a clinical study titled "Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)". Forodesine hydrochloride will be administered orally at a dose of 200 mg daily for 7 days each week for 4 weeks (cycle number 1). The drug will be administered once daily one hour prior to or two hours after meals. Patients will be evaluated after 1 full cycle of therapy (28 days).
What is the current status of trial NCT00289549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2005-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00289549?
The interventions under investigation include: forodesine hydrochloride (BCX-1777) (DRUG).
Who is sponsoring clinical trial NCT00289549?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.